How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "2802"
  ["article_id"]=>
  string(4) "2802"
  [1]=>
  string(73) "Lonza to manufacture Alector’s mAb drug candidates for Ph I trial "
  ["article_title"]=>
  string(73) "Lonza to manufacture Alector’s mAb drug candidates for Ph I trial "
  [2]=>
  string(152) "Lonza will provide manufacturing for Alectorâs Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to"
  ["short_description"]=>
  string(152) "Lonza will provide manufacturing for Alectorâs Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to"
  [3]=>
  string(180) "Lonza will provide manufacturing for Alectorâs Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to be operational by mid-2020."
  ["description"]=>
  string(180) "Lonza will provide manufacturing for Alectorâs Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to be operational by mid-2020."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(175) "https://www.outsourcing-pharma.com/Article/2019/05/09/Alector-taps-Lonza-to-manufacture-for-its-early-phase-drug-candidates?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(175) "https://www.outsourcing-pharma.com/Article/2019/05/09/Alector-taps-Lonza-to-manufacture-for-its-early-phase-drug-candidates?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-05-09 22:49:00"
  ["add_date"]=>
  string(19) "2019-05-09 22:49:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:25:13"
  ["create_at"]=>
  string(19) "2019-05-23 14:25:13"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Lonza to manufacture Alector’s mAb drug candidates for Ph I trial

Lonza will provide manufacturing for Alectorâs Phase I drug candidates for neurodegenerative diseases from its Switze

array(40) {
  [0]=>
  string(4) "2803"
  ["article_id"]=>
  string(4) "2803"
  [1]=>
  string(54) "Pfizer expands rare disease pipeline with $820m buyout"
  ["article_title"]=>
  string(54) "Pfizer expands rare disease pipeline with $820m buyout"
  [2]=>
  string(128) "Pfizer will acquire Therachon to gain access to TA-46, the biotechâs lead drug candidate for the treatment of achondroplasia."
  ["short_description"]=>
  string(128) "Pfizer will acquire Therachon to gain access to TA-46, the biotechâs lead drug candidate for the treatment of achondroplasia."
  [3]=>
  string(128) "Pfizer will acquire Therachon to gain access to TA-46, the biotechâs lead drug candidate for the treatment of achondroplasia."
  ["description"]=>
  string(128) "Pfizer will acquire Therachon to gain access to TA-46, the biotechâs lead drug candidate for the treatment of achondroplasia."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(140) "https://www.biopharma-reporter.com/Article/2019/05/09/Pfizer-acquires-Therachon-for-350m?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(140) "https://www.biopharma-reporter.com/Article/2019/05/09/Pfizer-acquires-Therachon-for-350m?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-05-09 22:33:00"
  ["add_date"]=>
  string(19) "2019-05-09 22:33:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:25:13"
  ["create_at"]=>
  string(19) "2019-05-23 14:25:13"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Pfizer expands rare disease pipeline with $820m buyout

Pfizer will acquire Therachon to gain access to TA-46, the biotechâs lead drug candidate for the treatment of achondr

array(40) {
  [0]=>
  string(4) "2795"
  ["article_id"]=>
  string(4) "2795"
  [1]=>
  string(59) "New Guide to Help Consumers Navigate Genetic Health Testing"
  ["article_title"]=>
  string(59) "New Guide to Help Consumers Navigate Genetic Health Testing"
  [2]=>
  string(102) "In recent years, we have seen a growing array of direct-to-consumer (DTC) genetic testing products ..."
  ["short_description"]=>
  string(102) "In recent years, we have seen a growing array of direct-to-consumer (DTC) genetic testing products ..."
  [3]=>
  string(877) """In recent years, we have seen a growing array of direct-to-consumer (DTC) genetic testing products ..."
  ["description"]=>
  string(877) """In recent years, we have seen a growing array of direct-to-consumer (DTC) genetic testing products ..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "102"
  ["rss_id"]=>
  string(3) "102"
  [14]=>
  string(116) "http://feedproxy.google.com/~r/BiotechNow/~3/BdNYCVD_Siw/new-guide-to-help-consumers-navigate-genetic-health-testing"
  ["blog_url"]=>
  string(116) "http://feedproxy.google.com/~r/BiotechNow/~3/BdNYCVD_Siw/new-guide-to-help-consumers-navigate-genetic-health-testing"
  [15]=>
  string(19) "2019-05-09 21:42:15"
  ["add_date"]=>
  string(19) "2019-05-09 21:42:15"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:25:10"
  ["create_at"]=>
  string(19) "2019-05-23 14:25:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

New Guide to Help Consumers Navigate Genetic Health Testing

 

array(40) {
  [0]=>
  string(4) "1952"
  ["article_id"]=>
  string(4) "1952"
  [1]=>
  string(84) "Advisory body on drug misuse to provide framework on medical cannabis by end of 2019"
  ["article_title"]=>
  string(84) "Advisory body on drug misuse to provide framework on medical cannabis by end of 2019"
  [2]=>
  string(152) "The Advisory Council on the Misuse of Drugs (ACMD) has been asked to provide an outline framework on medical cannabis by the end of 2019, with the ai"
  ["short_description"]=>
  string(152) "The Advisory Council on the Misuse of Drugs (ACMD) has been asked to provide an outline framework on medical cannabis by the end of 2019, with the ai"
  [3]=>
  string(199) "The Advisory Council on the Misuse of Drugs (ACMD) has been asked to provide an outline framework on medical cannabis by the end of 2019, with the aim of having an initial view by the end of 2020."
  ["description"]=>
  string(199) "The Advisory Council on the Misuse of Drugs (ACMD) has been asked to provide an outline framework on medical cannabis by the end of 2019, with the aim of having an initial view by the end of 2020."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(163) "https://www.pharmaceutical-journal.com/news-and-analysis/news/advisory-body-on-drug-misuse-to-provide-framework-on-medical-cannabis-by-end-of-2019/20206487.article"
  ["blog_url"]=>
  string(163) "https://www.pharmaceutical-journal.com/news-and-analysis/news/advisory-body-on-drug-misuse-to-provide-framework-on-medical-cannabis-by-end-of-2019/20206487.article"
  [15]=>
  string(19) "2019-05-09 16:54:00"
  ["add_date"]=>
  string(19) "2019-05-09 16:54:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:53"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Advisory body on drug misuse to provide framework on medical cannabis by end of 2019

The Advisory Council on the Misuse of Drugs (ACMD) has been asked to provide an outline framework on medical cannabis

array(40) {
  [0]=>
  string(4) "2063"
  ["article_id"]=>
  string(4) "2063"
  [1]=>
  string(45) "Twenty Years of Driving the Future of Surgery"
  ["article_title"]=>
  string(45) "Twenty Years of Driving the Future of Surgery"
  [2]=>
  string(150) "GETINGE, Sweden, May 9, 2019 /PRNewswire/ -- For the last ten years Getinge has been a driving force when it comes to Hybrid operating rooms (Hybrid O"
  ["short_description"]=>
  string(150) "GETINGE, Sweden, May 9, 2019 /PRNewswire/ -- For the last ten years Getinge has been a driving force when it comes to Hybrid operating rooms (Hybrid O"
  [3]=>
  string(298) "
GETINGE, Sweden, May 9, 2019 /PRNewswire/ -- For the last ten years Getinge has been a driving force when it comes to Hybrid operating rooms (Hybrid ORs), a place where both diagnostics and therapies takes place. But even ten years before that we were already pioneering this area, it was...
"
  ["description"]=>
  string(298) "
GETINGE, Sweden, May 9, 2019 /PRNewswire/ -- For the last ten years Getinge has been a driving force when it comes to Hybrid operating rooms (Hybrid ORs), a place where both diagnostics and therapies takes place. But even ten years before that we were already pioneering this area, it was...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(105) "https://www.prnewswire.com:443/news-releases/twenty-years-of-driving-the-future-of-surgery-300847071.html"
  ["blog_url"]=>
  string(105) "https://www.prnewswire.com:443/news-releases/twenty-years-of-driving-the-future-of-surgery-300847071.html"
  [15]=>
  string(19) "2019-05-09 16:15:00"
  ["add_date"]=>
  string(19) "2019-05-09 16:15:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:23"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Twenty Years of Driving the Future of Surgery

GETINGE, Sweden, May 9, 2019 /PRNewswire/ -- For the last ten years Getinge has been a driving force when it comes to

array(40) {
  [0]=>
  string(4) "2064"
  ["article_id"]=>
  string(4) "2064"
  [1]=>
  string(112) "Die Emaar Hospitality Group führt eine einzelne App für alle Hotel-, Hospitality- und Freizeitangebote ein"
  ["article_title"]=>
  string(112) "Die Emaar Hospitality Group führt eine einzelne App für alle Hotel-, Hospitality- und Freizeitangebote ein"
  [2]=>
  string(150) "DUBAI, VAE, 9. Mai 2019 /PRNewswire/ -- Die Emaar Hospitality Group, das Hospitality- und Freizeitunternehmen des globalen Immobilienentwicklers Emaar"
  ["short_description"]=>
  string(150) "DUBAI, VAE, 9. Mai 2019 /PRNewswire/ -- Die Emaar Hospitality Group, das Hospitality- und Freizeitunternehmen des globalen Immobilienentwicklers Emaar"
  [3]=>
  string(298) "
DUBAI, VAE, 9. Mai 2019 /PRNewswire/ -- Die Emaar Hospitality Group, das Hospitality- und Freizeitunternehmen des globalen Immobilienentwicklers Emaar Properties, hat eine vollständig integrierte mobile App eingeführt, die alle Hotel-, Hospitality- und Freizeitangebote des Konzerns...
"
  ["description"]=>
  string(298) "
DUBAI, VAE, 9. Mai 2019 /PRNewswire/ -- Die Emaar Hospitality Group, das Hospitality- und Freizeitunternehmen des globalen Immobilienentwicklers Emaar Properties, hat eine vollständig integrierte mobile App eingeführt, die alle Hotel-, Hospitality- und Freizeitangebote des Konzerns...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(163) "https://www.prnewswire.com:443/news-releases/die-emaar-hospitality-group-fuhrt-eine-einzelne-app-fur-alle-hotel-hospitality-und-freizeitangebote-ein-870902491.html"
  ["blog_url"]=>
  string(163) "https://www.prnewswire.com:443/news-releases/die-emaar-hospitality-group-fuhrt-eine-einzelne-app-fur-alle-hotel-hospitality-und-freizeitangebote-ein-870902491.html"
  [15]=>
  string(19) "2019-05-09 15:40:00"
  ["add_date"]=>
  string(19) "2019-05-09 15:40:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:23"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Die Emaar Hospitality Group führt eine einzelne App für alle Hotel-, Hospitality- un

DUBAI, VAE, 9. Mai 2019 /PRNewswire/ -- Die Emaar Hospitality Group, das Hospitality- und Freizeitunternehmen des glo

array(40) {
  [0]=>
  string(4) "2065"
  ["article_id"]=>
  string(4) "2065"
  [1]=>
  string(108) "Winning Projects Announced for the 2019 Elsevier Foundation-ISC3 Green & Sustainable Chemistry Challenge"
  ["article_title"]=>
  string(108) "Winning Projects Announced for the 2019 Elsevier Foundation-ISC3 Green & Sustainable Chemistry Challenge"
  [2]=>
  string(150) "DRESDEN, Germany, May 9, 2019 /PRNewswire/ -- Two new chemistry solutions that use a new green technique to remove toxic metal from wastewater and imp"
  ["short_description"]=>
  string(150) "DRESDEN, Germany, May 9, 2019 /PRNewswire/ -- Two new chemistry solutions that use a new green technique to remove toxic metal from wastewater and imp"
  [3]=>
  string(296) "
DRESDEN, Germany, May 9, 2019 /PRNewswire/ -- Two new chemistry solutions that use a new green technique to remove toxic metal from wastewater and improve pollination and ecosystem health with the help of butterflies have won the Elsevier Foundation-ISC3 Green and Sustainable Chemistry...
"
  ["description"]=>
  string(296) "
DRESDEN, Germany, May 9, 2019 /PRNewswire/ -- Two new chemistry solutions that use a new green technique to remove toxic metal from wastewater and improve pollination and ecosystem health with the help of butterflies have won the Elsevier Foundation-ISC3 Green and Sustainable Chemistry...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(163) "https://www.prnewswire.com:443/news-releases/winning-projects-announced-for-the-2019-elsevier-foundation-isc3-green--sustainable-chemistry-challenge-300847044.html"
  ["blog_url"]=>
  string(163) "https://www.prnewswire.com:443/news-releases/winning-projects-announced-for-the-2019-elsevier-foundation-isc3-green--sustainable-chemistry-challenge-300847044.html"
  [15]=>
  string(19) "2019-05-09 15:25:00"
  ["add_date"]=>
  string(19) "2019-05-09 15:25:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:23"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Winning Projects Announced for the 2019 Elsevier Foundation-ISC3 Green & Sustainable C

DRESDEN, Germany, May 9, 2019 /PRNewswire/ -- Two new chemistry solutions that use a new green technique to remove to

array(40) {
  [0]=>
  string(4) "2037"
  ["article_id"]=>
  string(4) "2037"
  [1]=>
  string(143) "Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai"
  ["article_title"]=>
  string(143) "Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai"
  [2]=>
  string(143) "Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai"
  ["short_description"]=>
  string(143) "Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai"
  [3]=>
  string(202) "
Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai
"
  ["description"]=>
  string(202) "
Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(210) "http://www.globenewswire.com/news-release/2019/05/09/1819995/0/en/Helsinn-and-Mundipharma-China-Pharmaceutical-together-announce-the-launch-of-ALOXI-IV-in-China-and-a-Co-Detailing-collaboration-in-Shanghai.html"
  ["blog_url"]=>
  string(210) "http://www.globenewswire.com/news-release/2019/05/09/1819995/0/en/Helsinn-and-Mundipharma-China-Pharmaceutical-together-announce-the-launch-of-ALOXI-IV-in-China-and-a-Co-Detailing-collaboration-in-Shanghai.html"
  [15]=>
  string(19) "2019-05-09 15:00:00"
  ["add_date"]=>
  string(19) "2019-05-09 15:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:08"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV

Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI 

array(40) {
  [0]=>
  string(4) "2038"
  ["article_id"]=>
  string(4) "2038"
  [1]=>
  string(74) "Terveystalo Plc: Terveystalo Group Interim report 1 January -31 March 2019"
  ["article_title"]=>
  string(74) "Terveystalo Plc: Terveystalo Group Interim report 1 January -31 March 2019"
  [2]=>
  string(59) "Growth in all customer groups, Attendo integration on track"
  ["short_description"]=>
  string(59) "Growth in all customer groups, Attendo integration on track"
  [3]=>
  string(77) "
Growth in all customer groups, Attendo integration on track
"
  ["description"]=>
  string(77) "
Growth in all customer groups, Attendo integration on track
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(143) "http://www.globenewswire.com/news-release/2019/05/09/1819958/0/en/Terveystalo-Plc-Terveystalo-Group-Interim-report-1-January-31-March-2019.html"
  ["blog_url"]=>
  string(143) "http://www.globenewswire.com/news-release/2019/05/09/1819958/0/en/Terveystalo-Plc-Terveystalo-Group-Interim-report-1-January-31-March-2019.html"
  [15]=>
  string(19) "2019-05-09 14:00:00"
  ["add_date"]=>
  string(19) "2019-05-09 14:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:08"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Terveystalo Plc: Terveystalo Group Interim report 1 January -31 March 2019

Growth in all customer groups, Attendo integration on track

array(40) {
  [0]=>
  string(4) "4891"
  ["article_id"]=>
  string(4) "4891"
  [1]=>
  string(77) "International Congress And Exhibition on Endocrine And Diabetic Complications"
  ["article_title"]=>
  string(77) "International Congress And Exhibition on Endocrine And Diabetic Complications"
  [2]=>
  string(158) "Conference Series LLC LTD invites you to join us at the “International Congress and Exhibition on Endocrinology and Diabetic Complications” where "
  ["short_description"]=>
  string(158) "Conference Series LLC LTD invites you to join us at the “International Congress and Exhibition on Endocrinology and Diabetic Complications” where "
  [3]=>
  string(515) "Conference Series LLC LTD invites you to join us at the “International Congress and Exhibition on Endocrinology and Diabetic Complications” where you will be assured to have a meaningful experience with scholars from around the world. The organizing committee looks forward to meeting you all at Sydney, Australia on October 14-15, 2019.&#nlMeet the Global Inspiring experts and speakers at our International Congress and Exhibition on Endocrinology and Diabetic Complications 2019 which will focus i..."
  ["description"]=>
  string(515) "Conference Series LLC LTD invites you to join us at the “International Congress and Exhibition on Endocrinology and Diabetic Complications” where you will be assured to have a meaningful experience with scholars from around the world. The organizing committee looks forward to meeting you all at Sydney, Australia on October 14-15, 2019.&#nlMeet the Global Inspiring experts and speakers at our International Congress and Exhibition on Endocrinology and Diabetic Complications 2019 which will focus i..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(109) "https://www.pharmiweb.com/event/international-congress-and-exhibition-on-endocrine-and-diabetic-complications"
  ["blog_url"]=>
  string(109) "https://www.pharmiweb.com/event/international-congress-and-exhibition-on-endocrine-and-diabetic-complications"
  [15]=>
  string(19) "2019-05-09 13:06:45"
  ["add_date"]=>
  string(19) "2019-05-09 13:06:45"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:12:08"
  ["create_at"]=>
  string(19) "2019-09-27 14:12:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

International Congress And Exhibition on Endocrine And Diabetic Complications

Conference Series LLC LTD invites you to join us at the “International Congress and Exhibition on Endocrinology an

array(40) {
  [0]=>
  string(4) "2492"
  ["article_id"]=>
  string(4) "2492"
  [1]=>
  string(103) "Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic"
  ["article_title"]=>
  string(103) "Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic"
  [2]=>
  string(150) "FOSTER CITY, Calif.--(BUSINESS WIRE)--May 9, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will donate Truvada for PrEP® (em"
  ["short_description"]=>
  string(150) "FOSTER CITY, Calif.--(BUSINESS WIRE)--May 9, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will donate Truvada for PrEP® (em"
  [3]=>
  string(245) "FOSTER CITY, Calif.--(BUSINESS WIRE)--May 9, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will donate Truvada for PrEP® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.S. Centers for..."
  ["description"]=>
  string(245) "FOSTER CITY, Calif.--(BUSINESS WIRE)--May 9, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will donate Truvada for PrEP® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.S. Centers for..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(279) "https://www.drugs.com/clinical_trials/gilead-sciences-provide-free-truvada-prep-support-u-s-initiative-end-hiv-epidemic-18138.html?utm_source=ddc&utm_medium=rss&utm_campaign=Gilead+Sciences+to+Provide+Free+Truvada+for+PrEP%C2%AE+to+Support+U.S.+Initiative+to+End+the+HIV+Epidemic"
  ["blog_url"]=>
  string(279) "https://www.drugs.com/clinical_trials/gilead-sciences-provide-free-truvada-prep-support-u-s-initiative-end-hiv-epidemic-18138.html?utm_source=ddc&utm_medium=rss&utm_campaign=Gilead+Sciences+to+Provide+Free+Truvada+for+PrEP%C2%AE+to+Support+U.S.+Initiative+to+End+the+HIV+Epidemic"
  [15]=>
  string(19) "2019-05-09 13:05:08"
  ["add_date"]=>
  string(19) "2019-05-09 13:05:08"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:34"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 9, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will do

array(40) {
  [0]=>
  string(4) "2039"
  ["article_id"]=>
  string(4) "2039"
  [1]=>
  string(143) "ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S.,  Canada and Europe "
  ["article_title"]=>
  string(143) "ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S.,  Canada and Europe "
  [2]=>
  string(160) "Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the"
  ["short_description"]=>
  string(160) "Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the"
  [3]=>
  string(646) "
Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced initiation of the Phase 3 development program of its orally administered, gonadotropin-releasing hormone (GnRH) receptor antagonist, linzagolix, for the treatment of endometriosis-associated pain, which includes the EDELWEISS 2 and EDELWEISS 3  clinical trials.   
"
  ["description"]=>
  string(646) "
Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced initiation of the Phase 3 development program of its orally administered, gonadotropin-releasing hormone (GnRH) receptor antagonist, linzagolix, for the treatment of endometriosis-associated pain, which includes the EDELWEISS 2 and EDELWEISS 3  clinical trials.   
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(210) "http://www.globenewswire.com/news-release/2019/05/09/1819921/0/en/ObsEva-SA-Announces-Initiation-of-Phase-3-EDELWEISS-2-and-3-Trials-of-Linzagolix-for-Endometriosis-Associated-Pain-in-U-S-Canada-and-Europe.html"
  ["blog_url"]=>
  string(210) "http://www.globenewswire.com/news-release/2019/05/09/1819921/0/en/ObsEva-SA-Announces-Initiation-of-Phase-3-EDELWEISS-2-and-3-Trials-of-Linzagolix-for-Endometriosis-Associated-Pain-in-U-S-Canada-and-Europe.html"
  [15]=>
  string(19) "2019-05-09 13:00:00"
  ["add_date"]=>
  string(19) "2019-05-09 13:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:08"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endom

Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NAS